[
    [
        {
            "time": "2018-03-15",
            "original_text": "Most Analysts Currently Call Boston Scientific a ‘Buy’",
            "features": {
                "keywords": [
                    "Analysts",
                    "Boston Scientific",
                    "Buy"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Most Analysts Currently Call Boston Scientific a ‘Buy’",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-16",
            "original_text": "The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst Blog",
                    "Abbott",
                    "Gilead",
                    "FedEx",
                    "Archer Daniels",
                    "CBRE"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech",
                    "logistics",
                    "agriculture",
                    "real estate"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-17",
            "original_text": "Abbott's DRG Therapy Now Covered by Aetna, To Boost Uptake",
            "features": {
                "keywords": [
                    "Abbott",
                    "DRG Therapy",
                    "Aetna",
                    "Boost Uptake"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Abbott's DRG Therapy Now Covered by Aetna, To Boost Uptake",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-18",
            "original_text": "Abbott's DRG Therapy Now Covered by Aetna, To Boost Uptake",
            "features": {
                "keywords": [
                    "Abbott",
                    "DRG Therapy",
                    "Aetna",
                    "Boost Uptake"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Abbott's DRG Therapy Now Covered by Aetna, To Boost Uptake",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]